Cigna price target raised to $400 from $380 at Truist

Truist analyst David MacDonald raised the firm’s price target on Cigna to $400 from $380 and keeps a Buy rating on the shares. The firm is bullish on Cigna after an upbeat investor day highlighting the wide range of growth opportunities across the company’s complementary platforms, new initiatives around GLP-1s, behavioral and biosimilars, and a bump to its long-term growth outlook, the analyst tells investors in a research note. Truist adds that it continues to like Cigna’s strong positioning within the high growth specialty and care services markets and sees share gain opportunity further underpinning core trends.